Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

N/A

1(20.0%)

Phase 2

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 3(2)

N/A(1)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04392544Active Not Recruiting

Intestinal Inflammation in CF Patients

Role: collaborator

NCT03070522Phase 3Completed

Prednisone in Cystic Fibrosis Pulmonary Exacerbations

Role: collaborator

NCT02810691Not ApplicableCompleted

The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis

Role: collaborator

NCT00528190Phase 4Completed

Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis

Role: collaborator

NCT01885169Unknown

LAIV (Flumist®) Administration in CF Patients

Role: collaborator

NCT00817180Phase 2Completed

Long-term Study, Comparing Vest Therapy to Positive Expiratory Pressure (PEP) Therapy in the Treatment of Cystic Fibrosis

Role: collaborator

NCT00635141Phase 3Completed

The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis

Role: collaborator

All 7 trials loaded